Targeted therapies such as Interleukin and JAK inhibitors are making inroads into the Ulcerative Colitis market owing to better clinical profile and also patient convenient dosing
LAS VEGAS, Oct. 26, 2021 /PRNewswire/ -- DelveInsight's Ulcerative Colitis Market report offers a detailed comprehension of the Ulcerative Colitis market size by treatment, epidemiology, and emerging therapies. The report also provides an understanding of Ulcerative Colitis market share of the individual therapies, current and forecasted Ulcerative Colitis market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
According to an estimate by DelveInsight, the highest Ulcerative Colitis prevalent cases in the 7MM were found in the United States with 1,008,823 which accounted for nearly 46% of the total 7MM cases, in the year 2020. The market size of Ulcerative Colitis is expected to grow at a CAGR of 9.5% in the 7MM for the study period 2018-2030.
Key pharma players working proactively in the Ulcerative Colitis therapeutic market are Gilead Sciences, Galapagos NV, AbbVie, Eli Lilly and Company, Arena Pharmaceuticals, Janssen (Johnson & Johnson), Theravance Biopharma, Landos Biopharma, and several others in the clinical development stage for Ulcerative Colitis will lead to a significant increase in the market size during the forecast period.
The key therapies expected to launch in the Ulcerative Colitis market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi (Risankizumab), Mirikizumab (LY-3074828), Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11, and others.
According to DelveInsight analysis, the Ulcerative Colitis market is expected to rise in the coming years due to the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, increasing prevalence of Ulcerative Colitis, and new biomarkers for diagnosis of Ulcerative Colitis.
The major reason behind the Ulcerative Colitis market upsurge would be the improvement in the rise in the number of healthcare spending across the world.
Two major types of Inflammatory Bowel Disease (IBD) are Ulcerative Colitis (UC) and Crohn's Disease (CD). Ulcerative Colitis is limited to the colon or large intestine. Approximately 10% of cases of IBD exhibit the features of both Ulcerative Colitis and Crohn's Disease. These are typically known as Indeterminate Colitis (IC).
There are different types of Ulcerative Colitis, categorized by the cause of the disease: Ulcerative proctitis, Proctosigmoiditis, Left-sided colitis (also limited or distal colitis), Pancolitis, and Extensive Colitis. There is no single test to diagnose Ulcerative Colitis, instead, the IBD team takes into consideration the symptoms together with the results of Endoscopies, Biopsies, Blood and Stool tests, X-rays, and Imaging Procedures.
In Ulcerative Colitis treatment, the primary purpose is to help patients properly control their immune systems. A variety of treatment options may help the patient remain in control of the condition and lead a complete and rewarding life, but there is no proven cure for Ulcerative Colitis and flare-ups may recur.
Types of medications currently used for the Ulcerative Colitis treatment purpose are Aminosalicylates, Corticosteroids, Immunomodulators, Biologic therapies (Adalimumab, Golimumab, Infliximab, Ustekinumab, Vedolizumab,Janus kinase (JAK) inhibitors, and sphingosine 1-phosphate (S1P) receptor modulators. At times, combination therapy and dietary supplementation are also prescribed.Medications like Aminosalicylates, Corticosteroids, Immunomodulators, Biologic therapies, Janus kinase (JAK) inhibitors, and sphingosine 1-phosphate (S1P) receptor modulators can suppress the inflammation.
Ulcerative Colitis pipeline therapies with better clinical profiles include drugs like Risankizumab (ABBV-066), an anti-IL-23 antibody being investigated by AbbVie and Boehringer Ingelheim for the treatment of Ulcerative Colitis. Mirikizumab (LY3074828) is another investigational drug being developed by Eli Lilly and Company to treat Ulcerative Colitis. Few of the novel, oral breakthrough Ulcerative Colitis treatment therapy include Filgotinib by Galapagos, in collaboration with Gilead, TD-1473 by Theravance Biopharma and Janssen, Etrasimod (APD334) discovered by Arena, and BT 11 by Landos Biopharma.
The current therapeutic landscape of Ulcerative Colitis in the 7MM is driven by several approved therapies. Also, the Ulcerative Colitis market is expected to surge due to factors such as the increasing prevalence of Ulcerative Colitis, entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, new biomarkers for diagnosis of Ulcerative Colitis and also the involvement of digital technology for diagnosis and treatment.
A high number of undiagnosed and unreported cases contribute to the lack of awareness of Ulcerative Colitis. The entry of biosimilars in the Ulcerative Colitis Market, insufficient knowledge of the disease, and significant drawbacks of existing therapeutic options may act as certain obstructions in the Ulcerative Colitis market.
DelveInsight's, "Crohn's Disease – Pipeline Insight, 2021," report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn's Disease pipeline landscape, which includes key companies like Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, and many others.
DelveInsight's 'Chronic pancreatitis (CP) - Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the disease, current treatment practice/algorithm, market drivers, market barriers, unmet needs, and key companies involved like Aptalis Pharma, Digestive Care Inc, Kangen Pharmaceuticals, AzurRx BioPharma, and several others.
DelveInsight's 'Ascites-Market Insights, Epidemiology, and Market Forecast–2030' report deliver an in-depth understanding of the Ascites, current treatment practice/algorithm, market drivers, market barriers, unmet needs, and key companies involved like BioVie, Noorik Biopharmaceuticals AG, and others.
DelveInsight's 'Chronic Venous Ulceration (CVU) - Market Insights, Epidemiology and Market Forecast– 2030' report delivers an in-depth understanding of the CVU, historical and forecasted epidemiology, market drivers, market barriers, and key companies involved like Merck, Bristol-Myers Squibb, Eli Lilly, Taiho Oncology, Hutchison Medipharma Ltd, G1 Therapeutics, Isofol Medical, AB Science, Seagen, Effector Therapeutics, and many more.
DelveInsight's, "Ulcerative Proctitis - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Ulcerative Proctitis pipeline landscape, which includes companies like First Wave Bio, Dr Falk Pharma, Alfasigma, Cristcot LLC, and several others.
Autoimmune and inflammatory diseases are common with a diverse array. Different organs are affected, and significant variability is seen among the individuals when talking about the severity, or the response to the treatment.
DelveInsight is a pioneer in stipulating state-of-the-art services to the clients, also serving as a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.